181 related articles for article (PubMed ID: 37453737)
1. Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials.
Ruperto N; Lovell DJ; Berman A; Anton J; Viola DO; Lauwerys B; Rama ME; Bohnsack J; Breedt J; Fischbach M; Lutz T; Minden K; Ally M; Rubio-Pérez N; Gervais E; Van Zyl R; Wong R; Askelson M; Martini A; Brunner HI;
J Rheumatol; 2023 Nov; 50(11):1471-1480. PubMed ID: 37453737
[TBL] [Abstract][Full Text] [Related]
2. Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD.
Bardan I; Fagerli KM; Sexton J; Kvien TK; Bakland G; Mielnik P; Hu Y; Lien G; Flatø B; Molberg Ø; Kristianslund EK; Aga AB
J Rheumatol; 2023 Apr; 50(4):538-547. PubMed ID: 36379571
[TBL] [Abstract][Full Text] [Related]
3. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
5. Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.
Brunner HI; Wong R; Nys M; Kou TD; Dominique A; Martini A; Lovell DJ; Ruperto N;
Paediatr Drugs; 2020 Dec; 22(6):653-672. PubMed ID: 33029724
[TBL] [Abstract][Full Text] [Related]
6. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.
Brunner HI; Tzaribachev N; Vega-Cornejo G; Louw I; Berman A; Calvo Penadés I; Antón J; Ávila-Zapata F; Cuttica R; Horneff G; Foeldvari I; Keltsev V; Kingsbury DJ; Viola DO; Joos R; Lauwerys B; Paz Gastañaga ME; Rama ME; Wouters C; Bohnsack J; Breedt J; Fischbach M; Lutz T; Minden K; Miraval T; Ally MMTM; Rubio-Pérez N; Solau Gervais E; van Zyl R; Li X; Nys M; Wong R; Banerjee S; Lovell DJ; Martini A; Ruperto N;
Arthritis Rheumatol; 2018 Jul; 70(7):1144-1154. PubMed ID: 29481737
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
[TBL] [Abstract][Full Text] [Related]
9. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.
Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G
Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924
[TBL] [Abstract][Full Text] [Related]
10. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
[TBL] [Abstract][Full Text] [Related]
11. Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis.
Ruperto N; Brunner HI; Tzaribachev N; Vega-Cornejo G; Louw I; Cimaz R; Dare J; Espada G; Faugier E; Ferrandiz M; Gerloni V; Quartier P; Silva CA; Wagner-Weiner L; Gandhi Y; Passarell J; Nys M; Wong R; Martini A; Lovell DJ;
J Rheumatol; 2021 Jul; 48(7):1073-1081. PubMed ID: 33452173
[TBL] [Abstract][Full Text] [Related]
12. The use of methotrexate in children with rheumatic diseases.
Gutiérrez-Suárez R; Burgos-Vargas R
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
[TBL] [Abstract][Full Text] [Related]
13. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients.
Fernández-Díaz C; Atienza-Mateo B; Castañeda S; Melero-Gonzalez RB; Ortiz-SanJuan F; Loricera J; Casafont-Solé I; Rodríguez-García S; Aguilera-Cros C; Villa-Blanco I; Raya-Alvarez E; Ojeda-García C; Bonilla G; López-Robles A; Arboleya L; Narváez J; Cervantes E; Maiz O; Alvarez-Rivas MN; Cabezas I; Salgado E; Hidalgo-Calleja C; Fernández S; Fernández JC; Ferraz-Amaro I; González-Gay MA; Blanco R;
Rheumatology (Oxford); 2021 Dec; 61(1):299-308. PubMed ID: 33779697
[TBL] [Abstract][Full Text] [Related]
14. Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival.
Thiele F; Klein A; Klotsche J; Windschall D; Dressler F; Kuemmerle-Deschner J; Minden K; Foeldvari I; Foell D; Mrusek S; Oommen PT; Horneff G
Rheumatology (Oxford); 2023 Jun; 62(6):2230-2238. PubMed ID: 36222562
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
16. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
Gandhi Y; Passarell JA; Roy A; Murthy B
J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
[TBL] [Abstract][Full Text] [Related]
18. [Biologics in the treatment of juvenile idiopathic arthritis : A comparison of mono- and combination therapy with synthetic DMARDs].
Klein A
Z Rheumatol; 2019 Sep; 78(7):599-609. PubMed ID: 31087133
[TBL] [Abstract][Full Text] [Related]
19. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y
Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
Brunner HI; Ruperto N; Zuber Z; Keane C; Harari O; Kenwright A; Lu P; Cuttica R; Keltsev V; Xavier RM; Calvo I; Nikishina I; Rubio-Pérez N; Alexeeva E; Chasnyk V; Horneff G; Opoka-Winiarska V; Quartier P; Silva CA; Silverman E; Spindler A; Baildam E; Gámir ML; Martin A; Rietschel C; Siri D; Smolewska E; Lovell D; Martini A; De Benedetti F; ;
Ann Rheum Dis; 2015 Jun; 74(6):1110-7. PubMed ID: 24834925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
